The US Food and Drug Administration (FDA) has approved Amgen’s Repatha (evolocumab) to treat paediatric patients aged ten years and above with heterozygous familial hypercholesterolemia (HeFH). The drug received approval as
The World Health Organization (WHO) has added Regeneron Pharmaceuticals and Roche’s Covid-19 antibody drug cocktail to the list of treatments for Covid-19 patients. The agency has recommended the
AstraZeneca has entered a strategic, long-term research collaboration with biopharmaceutical firm VaxEquity to discover, develop and commercialise self-amplifying RNA (saRNA) therapeutics platform. VaxEquity was founded last year by
Tonix Pharmaceuticals has expanded its research partnership with Columbia University in the US for the development of tailored Covid-19 vaccines and treatments with precision medicine. The move follows
Canadian biotechnology firm AbCellera has signed a collaboration and licence agreement with Everest Medicines to advance new antibody therapies. Under the multi-year agreement, Everest will obtain rights to
The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a booster dose of Pfizer-BioNTech’s Covid-19 vaccine. The regulatory agency approved the booster dose
German pharmaceutical firm Boehringer Ingelheim has acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches. The financial details of the transaction were
The US Food and Drug Administration (FDA) has approved Samsung Bioepis and Biogen’s Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab). Byooviz is an anti-vascular endothelial growth factor (VEGF)
Pfizer and its partner BioNTech have announced positive topline results from a pivotal trial of their Covid-19 vaccine in children aged 5 to 11 years. The Phase II/III
Spanish healthcare firm Grifols has agreed to acquire 100% stake in Tiancheng (Germany) Pharmaceutical from Tiancheng International Investment for $1.289bn (€1.1bn). Tiancheng Pharmaceutical owns 89.88% of Biotest ordinary
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.